Helix Biopharma Corp.
HBP.TO
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.52M | 2.37M | 2.39M | 845.00K | 796.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.26M | 7.02M | 6.78M | 4.54M | 4.20M |
| Operating Income | -7.26M | -7.02M | -6.78M | -4.54M | -4.20M |
| Income Before Tax | -7.15M | -6.85M | -6.80M | -4.56M | -4.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.15 | -6.85 | -6.80 | -4.56 | -4.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.15M | -6.85M | -6.80M | -4.56M | -4.19M |
| EBIT | -7.26M | -7.02M | -6.78M | -4.54M | -4.20M |
| EBITDA | -7.25M | -7.01M | -6.77M | -4.53M | -4.19M |
| EPS Basic | -0.14 | -0.14 | -0.14 | -0.11 | -0.10 |
| Normalized Basic EPS | -0.09 | -0.09 | -0.09 | -0.07 | -0.06 |
| EPS Diluted | -0.17 | -0.14 | -0.14 | -0.11 | -0.10 |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.09 | -0.07 | -0.06 |
| Average Basic Shares Outstanding | 193.85M | 185.76M | 179.31M | 167.15M | 164.52M |
| Average Diluted Shares Outstanding | 193.85M | 185.76M | 179.31M | 167.15M | 164.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |